Federal health advisors voted 17-1 against an experimental treatment for Lou Gehrig's disease dubbed NurOwn, although the FDA is not bound by the vote.
Health advisers overwhelmingly indicate Brainstorm's stem cell-based approach has not been shown effective for patients with the fatal muscle-wasting disease
THURSDAY, Sept. 28, 2023 (HealthDay News) – An advisory panel to the U.S. Food and Drug Administration on Wednesday voted resoundingly against recommending a stem cell-based experimental treatment for ALS.
FDA panel says no to experimental ALS drug medicalxpress.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from medicalxpress.com Daily Mail and Mail on Sunday newspapers.
FDA advisers vote against experimental ALS treatment pushed by patients register-herald.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from register-herald.com Daily Mail and Mail on Sunday newspapers.